A relatively new biologic treatment that is approved for treating rheumatoid arthritis is Tocilizumab (trade name Actemra and RoActemra). Tocilizumab is a humanised monoclonal antibody that targets interleukin-6 receptor (IL-6R), thus blocking interleukin-6 (IL-6) cytokine mediated signalling, which is known to play an important role in mediating inflammatory processes. 242 more words